Towards a future where breast cancer is no longer a life-threatening disease.
News
Barcelona / Nottingham, February 8th, 2024 - Source BioScience, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients, have signed an exclusive agreement to start offering the MAF Test® as a service in United Kingdom and Ireland. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.
Barcelona / Johannesburg, December 13th, 2023 - The Scientific Group, a leader in the IVD industry, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients have signed an agreement to start marketing MAF Test® in Sub-Saharan Africa. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.
Barcelona, 10 November 2023 - A team from IRB Barcelona led by ICREA researcher Dr. Roger Gomis, co-founder of Inbiomotion, has revealed the mechanism by which the MAF protein increases the risk of metastasis in breast cancer patients. This finding is a crucial step in understanding the molecular basis of metastasis and has relevant clinical implications for treatment.
The research team has detailed in the journal Nature Cell Biology how the MAF protein interacts with the estrogen receptor, a key element in the development of breast cancer, modifying its structure. This interaction leads to DNA restructuring, which allows the activation of genes that favor metastasis, particularly in response to estrogen. These findings imply that patients with high levels of MAF protein have a greater risk of developing metastasis.
Sant Cugat/Barcelona, 28 September 2023 - Palex Medical, a national leader in precision oncology, and Inbiomotion, a spin-off of IRB Barcelona and ICREA, have signed an agreement to start marketing MAF Test®, initially in Spain and Portugal. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.
Sant Cugat/Barcelona, 28 September 2023 - Palex Medical, a national leader in precision oncology, and Inbiomotion, a spin-off of IRB Barcelona and ICREA, have signed an agreement to start marketing MAF Test®, initially in Spain and Portugal. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.
Barcelona, December 20, 2022; Inbiomotion SL, a company developing a unique single-genebased biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, today announces the appointment of Ralf van den Berg as Chief Operating Officer.
MAF Test® analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment.
The MAF Test® was originally developed by Inbiomotion SL, and now Kreatech Biotechnology B.V (subsidiary of Leica Biosystems). completed the conformity assessment and drew up the declaration of conformity for in vitro medical devices.
Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis.
Alta Life Sciences is a new leading venture capital investment firm headquartered in Barcelona. The investment has been made through Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC.
Recently published: Bone Health in Cancer: ESMO Clinical Practice Guidelines (2020) for practice-changing precision medicine clinical routines devoted a section to discussed on Personalized Medicine.
The co-founder of Inbiomotion (Dr. Roger Gomis) and part of the team have published the results that validated MAF test ability to identify breast cancer patients that benefit from the use of bisphosphonate in adjuvancy in a second retrospective analysis of a prospective randomized clinical trial; NSABP-B34 (NCT00009945). (Paterson et al., J Clin Oncology, 2020; doi: 10.1200/JCO.2020.38.15_suppl.513). The results were presented at the ASCO meeting 2020 (Abstract #513).
Barcelona, Spain, 2018 - Inbiomotion S.L., a biotech company specialized in the development of companion diagnostics for the use of bone modifying agents, has just announced that has been granted of access to the NSABP B34 trial by the National Cancer Institute and NRG Oncology Group, US, to validate its proprietary biomarker.
Inbiomotion SL today announced the publication of the results of the long-term follow-up of Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAF Test® in the September issue of Journal of Bone Oncology.
Inbiomotion SL today announced the publication of the results of the Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAF Test® in the November issue of Lancet Oncology
The investment has been made through Caixa Innvierte BioMed II, a vehicle managed by Caixa Capital Risc, the venture capital arm of "la Caixa". The fund is driven by "la Caixa" and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme and has minority participation from the Institut Català de Finances.
Physicians currently have no tools to help them detect which breast cancer patients will suffer metastasis to the bone, a process that occurs in 15-20% of cases. A study led by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) and published today in JNCI has uncovered a gene that allows breast cancer cells to invade bones and create new tumours, or to metastasize.
Inbiomotion SL, a company focused on the development of a specific biomarker for the prediction of bone metastasis, has strengthened its board of directors with the appointment of Dr. David L. Lacey.
Inbiomotion SL, a company focused on the development of biomarkers for the prediction of bone metastasis, today announced the creation of its Scientific Advisory Board with renowned experts in various disciplines, including bone metastatic disease, biomarker development, translational research and medical oncology.
Inbiomotion SL, a company focused on the development of biomarkers for the prediction of bone metastasis, today announced the appointment of Dr. Jon Askaa, as non-executive Director, and Dr. Juan Carlos Tercero as Head of Product Development.
Ysios Capital, a leading Spanish life sciences venture capital firm, today announces that it has led the €2 million Series A financing of Inbiomotion SL, a spin-out company from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA focused on the development of biomarkers for the prediction of bone metastasis from primary tumor biopsies. Additional investors participating in the round include Fundació Vila Casas and JVRisk Technologies.
Together, we will drive new perspectives towards a future where breast cancer is no longer a life-threatening disease.
